1
|
Wang S, Peng D, Zhu H, Min W, Xue M, Wu R, Shao Y, Pan L, Zhu M. Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. Front Oncol 2022; 12:1053370. [PMID: 36568231 PMCID: PMC9773380 DOI: 10.3389/fonc.2022.1053370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Accepted: 11/17/2022] [Indexed: 12/13/2022] Open
Abstract
Despite the intriguing therapeutic prospects offered by immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) become an increasingly important safety issue. Herein, we report a patient with locally advanced colorectal cancer (LACRC) who received anti-programmed cell death protein 1 (PD-1) (tislelizumab) therapy, then developed weakness of the limbs and drooping eyelids. He experienced sequential irAEs including severe myasthenia gravis, myocarditis, and rhabdomyolysis. Although many irAEs caused by tislelizumab have been reported, the cooccurrence of severe myasthenia gravis, myocarditis, and rhabdomyolysis caused by tislelizumab has not been described. The patient responded well to methylprednisolone and intravenous immunoglobulin therapy. This case illustrates the severe toxicity caused by ICIs, highlighting the importance of early prevention, early diagnosis, and appropriate management of irAEs. Multidisciplinary discussions should be held to improve the prognosis of patients.
Collapse
Affiliation(s)
- Shengnan Wang
- Department of Neurology, The First Hospital of Jilin University, Changchun, China
| | - Danping Peng
- Department of Infectious Diseases, The First Hospital of Jilin University, Changchun, China
| | - Hao Zhu
- Department of Hepatology, The First Hospital of Jilin University, Changchun, China
| | - Wanwan Min
- Department of Neurology, The First Hospital of Jilin University, Changchun, China
| | - Mengru Xue
- Department of Neurology, The First Hospital of Jilin University, Changchun, China
| | - Rui Wu
- Department of Neurology, The First Hospital of Jilin University, Changchun, China
| | - Yanqing Shao
- Department of Neurology, The First Hospital of Jilin University, Changchun, China
| | - Lin Pan
- Clinical College, Jilin University, Changchun, China
| | - Mingqin Zhu
- Department of Neurology, The First Hospital of Jilin University, Changchun, China,*Correspondence: Mingqin Zhu,
| |
Collapse
|
2
|
Nissan E, Watad A, Cohen AD, Sharif K, Nissan J, Amital H, Shovman O, Bragazzi NL. Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph18083983. [PMID: 33920065 PMCID: PMC8068784 DOI: 10.3390/ijerph18083983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/04/2021] [Accepted: 04/06/2021] [Indexed: 11/16/2022]
Abstract
Polymyositis (PM) and dermatomyositis (DM) are autoimmune-mediated multisystemic myopathies, characterized mainly by proximal muscle weakness. A connection between epilepsy and PM/DM has not been reported previously. Our study aim is to evaluate this association. A case–control study was conducted, enrolling a total of 12,278 patients with 2085 cases (17.0%) and 10,193 subjects in the control group (83.0%). Student’s t-test was used to evaluate continuous variables, while the chi-square test was applied for the distribution of categorical variables. Log-rank test, Kaplan–Meier curves and multivariate Cox proportional hazards method were performed for the analysis regarding survival. Of the studied 2085 cases, 1475 subjects (70.7%) were diagnosed with DM, and 610 patients (29.3%) with PM. Participants enrolled as cases had a significantly higher rate of epilepsy (n = 48 [2.3%]) as compared to controls (n = 141 [1.4%], p < 0.0005). Using multivariable logistic regression analysis, PM was found only to be significantly associated with epilepsy (OR 2.2 [95%CI 1.36 to 3.55], p = 0.0014), whereas a non-significant positive trend was noted in DM (OR 1.51 [95%CI 0.99 to 2.30], p = 0.0547). Our data suggest that PM is associated with a higher rate of epilepsy compared to controls. Physicians should be aware of this comorbidity in patients with immune-mediated myopathies.
Collapse
Affiliation(s)
- Ella Nissan
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Abdulla Watad
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Arnon D. Cohen
- Chief Physician’s Office, Clalit Health Services, Tel Aviv 16250, Israel;
- Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8489325, Israel
| | - Kassem Sharif
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Johnatan Nissan
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
- Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer 5262000, Israel
| | - Howard Amital
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Ora Shovman
- Department of Medicine ‘B’ & Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer 5262000, Israel; (E.N.); (A.W.); (K.S.); (H.A.); (O.S.)
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel;
| | - Nicola Luigi Bragazzi
- Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, ON M3J 1P3, Canada
- Correspondence:
| |
Collapse
|
3
|
Cheng H, Huo L, Wang D, Xiang Y. Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis. J Gynecol Oncol 2020; 30:e99. [PMID: 31576691 PMCID: PMC6779614 DOI: 10.3802/jgo.2019.30.e99] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 05/13/2019] [Accepted: 05/18/2019] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVE To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS The medical records of 23 consecutive patients who were diagnosed with OC and DM and were treated at Peking Union Medical College Hospital (PUMCH) between 2002 and 2017 were reviewed. Propensity score matching method was used to match control group (OC patients without DM) at a ratio of 1:5. The correlation between OC and DM was measured using the Pearson correlation scatter plot and Pearson's r. Kaplan-Meier survival analysis and Cox proportional hazard regression analysis were performed to evaluate the prognostic factors. RESULTS After matching, 23 patients who have the concurrence of OC and DM (DM group) and 115 patients diagnosed with OC alone (No DM group) were included. The 5-year overall survival rates (71.6% vs. 51.8%, p=0.020) and 5-year progression-free survival (30.5% vs. 0%, p=0.018) were poorer in DM group. Correlation between serum cancer antigen 125 (CA 125) and creatine kinase (CK) level was observed in 12 patients. The time between OC and DM diagnosis is significant through univariable analysis (p=0.021) but not in multivariable analysis in patients who have the concurrence of OC and DM. CONCLUSION The concurrence of OC and DM as a paraneoplastic syndrome is rare and has a poor prognosis. The risk for patients diagnosed with DM is highest within 3 years before or after OC diagnosis. A correlation and a parallel clinical course exist between these 2 diseases.
Collapse
Affiliation(s)
- Hongyan Cheng
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR, China
| | - Lanqing Huo
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR, China
| | - Dan Wang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR, China
| | - Yang Xiang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR, China.
| |
Collapse
|
4
|
Baig S, Mecoli CA. Cancer and Idiopathic Inflammatory Myositis. CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY 2019. [DOI: 10.1007/s40674-019-00128-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
5
|
|
6
|
Paraneoplastic Necrotizing Myopathy Associated With Neuroendocrine Carcinoma. J Clin Neuromuscul Dis 2017; 19:98-99. [PMID: 29189558 DOI: 10.1097/cnd.0000000000000169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Tiniakou E, Mammen AL. Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. Clin Rev Allergy Immunol 2017; 52:20-33. [PMID: 26429706 DOI: 10.1007/s12016-015-8511-x] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases (collectively known as myositis) affecting the skeletal muscles as well as other organ systems such as skin, lungs, and joints. The primary forms of myositis include polymyositis (PM), dermatomyositis (PM), and immune-mediated necrotizing myopathy (IMNM). Patients with these diseases experience progressive proximal muscle weakness, have characteristic muscle biopsy findings, and produce autoantibodies that are associated with unique clinical features. One distinguishing feature of these patients is that they are also known to have an increased risk of cancer. Since the first description of the association in 1916, it has been extensively reported in the medical literature. However, there have been significant variations between the different studies with regard to the degree of cancer risk in patients with IIM. These discrepancies can, in part, be attributed to differences in the definition of malignancy-associated myositis used in different studies. In recent years, significant advances have been made in defining specific features of IIM that are associated with the development of malignancy. One of these has been myositis-specific antibodies (MSAs), which are linked to distinct clinical phenotypes and categorize patients into groups with more homogeneous features. Indeed, patients with certain MSAs seem to be at particularly increased risk of malignancy. This review attempts a systematic evaluation of research regarding the association between malignancy and myositis.
Collapse
Affiliation(s)
- Eleni Tiniakou
- Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Andrew L Mammen
- Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. .,Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 50 South Drive, Room 1146, Building 50, MSC 8024, Bethesda, MD, 20892, USA.
| |
Collapse
|
8
|
Poon SH, Stoddart L. Unexpected Cause of Rhabdomyolysis and Proximal Muscle Weakness. Arthritis Care Res (Hoboken) 2017; 69:1599-1605. [PMID: 28118531 DOI: 10.1002/acr.23200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 12/11/2016] [Accepted: 01/17/2017] [Indexed: 01/04/2023]
Affiliation(s)
- Samuel H Poon
- Manchester Veterans Administration Medical Center, Manchester, New Hampshire, and Harrington Memorial Hospital, Southbridge, Massachusetts
| | - Lanu Stoddart
- Harrington Memorial Hospital, Southbridge, Massachusetts
| |
Collapse
|
9
|
Whole-body MRI in adult inflammatory myopathies: Do we need imaging of the trunk? Eur Radiol 2015; 25:3499-507. [PMID: 25903718 DOI: 10.1007/s00330-015-3783-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Revised: 03/30/2015] [Accepted: 04/08/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To evaluate whether imaging of the trunk could be omitted in patients with inflammatory myopathies without losing diagnostic accuracy using a restricted whole-body magnetic resonance imaging (rWB-MRI) protocol. METHODS After approval by the institutional review board, this study was performed in 63 patients (male/female, 13/50; median age, 52 years; range, 20-81 years) with new-onset myopathic symptoms (group 1, n = 41) or previously diagnosed inflammatory myopathy (group 2, n = 22). After performing whole-body MRI (WB-MRI) at 3.0 Tesla, myositis and fatty atrophy were evaluated in different muscles by two independent radiologists. The intra-class correlation coefficient (ICC) was calculated to evaluate inter-observer reliability. RESULTS Acquisition time was 56:01 minutes for WB-MRI and 37:37 minutes (32.8 % shorter) for rWB-MRI. In group 1, 14 patients were diagnosed with inflammatory myopathy based on muscle biopsy. rWB-MRI and WB-MRI showed equal sensitivity (42.9 %) and specificity (100 %) for myositis, and showed equal sensitivity (71.4 %) and similar specificity (63.0 % and 48.1 %, respectively) for fatty atrophy. No myositis was found in the body trunk in any patient. Inter-observer reliability was between substantial and perfect (ICC, 0.77-1.00). CONCLUSIONS rWB-MRI showed diagnostic accuracy similar to WB-MRI for inflammatory myopathy at markedly reduced overall acquisition time. KEY POINTS • Whole-body MRI (WB-MRI) is a time-consuming imaging modality. • A shortened MRI protocol was evaluated for inflammatory myopathies. • The proposed protocol showed diagnostic accuracy similar to WB-MRI.
Collapse
|
10
|
Nunes JC, Rinnenthal JL, Allenbach Y, Lenze D, Hummel M, Jöhrens K, Walz R, Goebel HH, Heppner FL, Stenzel W. Proximal weakness in a patient with MALT lymphoma: a case report and discussion of possible pathogenesis. Neuropathol Appl Neurobiol 2015; 41:686-9. [PMID: 25763887 DOI: 10.1111/nan.12234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Accepted: 02/18/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Jean Costa Nunes
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany.,Department of Pathology, Universidade Federal de Santa Catarina, Florianópolis, Brazil
| | - Jan-Leo Rinnenthal
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Yves Allenbach
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Dido Lenze
- Department of Pathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Michael Hummel
- Department of Pathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Korinna Jöhrens
- Department of Pathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Roger Walz
- Internal Medicine, Universidade Federal de Santa Catarina, Florianópolis, Brazil
| | - Hans-Hilmar Goebel
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Frank L Heppner
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Werner Stenzel
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| |
Collapse
|
11
|
|